Andrew John Partridge
CIK 1758838 · Chief Growth Officer · last filed 2026-06-05
Andrew John Partridge is a Chief Growth Officer who has filed 5 SEC Form 4 insider transactions across 2 companies since 2020. The most recent filing shows the insider sold $91.1K of GRALV on Jun 5, 2026. Across all open-market trades the lifetime net is −$239.1K, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
2
5
-$239.1K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| GRAIL, Inc. (GRALV) Delisted | Chief Growth Officer | 163,738 | — | — | -$91.1K | 1 | 2026-06-05 |
| Turning Point Therapeutics, Inc. (TPTX) Delisted | EVP & Chief Commercial Officer | 38,361 | $76.01 | $2.92M | -$148.0K | 4 | 2022-02-11 |
Recent Filings
5 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-05 | GRAIL, Inc. (GRALV) Delisted | Sell (S) | −1,491 | -$91.1K | EDGAR |
| 2022-02-11 | Turning Point Therapeutics, Inc. (TPTX) Delisted | Mixed | +16,062 | -$8.0K | EDGAR |
| 2021-07-15 | Turning Point Therapeutics, Inc. (TPTX) Delisted | Sell (S) | −1,869 | -$140.0K | EDGAR |
| 2021-02-10 | Turning Point Therapeutics, Inc. (TPTX) Delisted | Grant (A) | +2,136 | $0 | EDGAR |
| 2020-07-14 | Turning Point Therapeutics, Inc. (TPTX) Delisted | Grant (A) | +21,500 | $0 | EDGAR |